Claff Tobias, Mahardhika Andhika B, Vaaßen Victoria J, Schlegel Jonathan G, Vielmuth Christin, Weiße Renato H, Sträter Norbert, Müller Christa E
PharmaCenter Bonn & Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, Bonn 53113, Germany.
Research Training Group 2873, University of Bonn, Bonn 53121, Germany.
ACS Pharmacol Transl Sci. 2024 Apr 29;7(5):1415-1425. doi: 10.1021/acsptsci.4c00051. eCollection 2024 May 10.
The adenosine A receptor (AAR) belongs to the rhodopsin-like G protein-coupled receptor (GPCR) family, which constitutes the largest class of GPCRs. Partial agonists show reduced efficacy as compared to physiological agonists and can even act as antagonists in the presence of a full agonist. Here, we determined an X-ray crystal structure of the partial AAR agonist 2-amino-6-[(1-imidazol-2-ylmethyl)sulfanyl]-4--hydroxyphenyl-3,5-pyridinedicarbonitrile (LUF5834) in complex with the AAR construct A-PSB2-bRIL, stabilized in its inactive conformation and being devoid of any mutations in the ligand binding pocket. The determined high-resolution structure (2.43 Å) resolved water networks and crucial binding pocket interactions. A direct hydrogen bond of the -hydroxy group of LUF5834 with T88 was observed, an amino acid that was mutated to alanine in the most frequently used AAR crystallization constructs thus preventing the discovery of its interactions in most of the previous AAR co-crystal structures. G protein dissociation studies confirmed partial agonistic activity of LUF5834 as compared to that of the full agonist -ethylcarboxamidoadenosine (NECA). In contrast to NECA, the partial agonist was still able to bind to the receptor construct locked in its inactive conformation by an S91K mutation, although with an affinity lower than that at the native receptor. This could explain the compound's partial agonistic activity: while full AAR agonists bind exclusively to the active conformation, likely following conformational selection, partial agonists bind to active as well as inactive conformations, showing higher affinity for the active conformation. This might be a general mechanism of partial agonism also applicable to other GPCRs.
腺苷 A 受体(AAR)属于视紫红质样 G 蛋白偶联受体(GPCR)家族,该家族构成了 GPCR 中最大的类别。与生理性激动剂相比,部分激动剂的效力降低,并且在存在完全激动剂的情况下甚至可以充当拮抗剂。在此,我们确定了部分 AAR 激动剂 2-氨基-6-[(1-咪唑-2-基甲基)硫烷基]-4-羟基苯基-3,5-吡啶二甲腈(LUF5834)与 AAR 构建体 A-PSB2-bRIL 形成复合物的 X 射线晶体结构,该构建体稳定在其无活性构象且配体结合口袋中没有任何突变。所确定的高分辨率结构(2.43 Å)解析了水网络和关键的结合口袋相互作用。观察到 LUF5834 的羟基与 T88 之间存在直接氢键,在最常用的 AAR 结晶构建体中,该氨基酸突变为丙氨酸,因此在大多数先前的 AAR 共晶体结构中无法发现其相互作用。G 蛋白解离研究证实,与完全激动剂 N-乙基羧基酰胺腺苷(NECA)相比,LUF5834 具有部分激动活性。与 NECA 不同,部分激动剂仍能够与通过 S91K 突变锁定在其无活性构象的受体构建体结合,尽管其亲和力低于在天然受体上的亲和力。这可以解释该化合物的部分激动活性:完全 AAR 激动剂可能遵循构象选择,仅与活性构象结合,而部分激动剂则与活性和无活性构象都结合,对活性构象显示出更高的亲和力。这可能是部分激动作用的一种普遍机制,也适用于其他 GPCR。